In re Rivastigmine Patent Litigation

MEMORANDUM AND ORDER

FRANCIS, United States Magistrate Judge.

This multidistrict litigation concerns the patent rights for rivastigmine tartrate (“ri*72vastigmine”), the active ingredient in Exelon, a medication marketed by Novartis Pharmaceutical Corporation (“NPC”) for the treatment of mild to moderate dementia of the Alzheimer’s type. NPC, together with Novartis Pharma AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively, “Novartis”), has brought actions alleging that the defendants, Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratory, Inc. (collectively, “Dr.…